Log In

Part Descriptions

LP14839-2   Plasmodium falciparum
Four species of the Plasmodium protozoa are considered true parasites of humans as they use humans almost exclusively as a natural intermediate host: P. falciparum, P. vivax, P. ovale and P. malariae. Malaria today is usually restricted to tropical and subtropical areas and altitudes below 1,500 m., although in the past malaria was endemic in much of North America, Europe and even parts of northern Asia, and today is still present on the Korean peninsula. However, this present distribution could be affected by climatic changes and population movements. P. falciparum is the most prevalent species and responsible for the most morbidity and mortality worldwide. Early detect is of paramount importance due to the incidence of cerebral malaria and drug resistance. Malarial infections caused by P. falciparum are the most likely to progress to severe, potentially fatal forms with central nervous system involvement (cerebral malaria), acute renal failure, severe anemia, or acute respiratory distress syndrome.[CDC] Source: Regenstrief LOINC, CDC

LP20149-8   Plasmodium
Malaria is a parasitic disease that is passed from one human to another by the bite of an infected Anopheles mosquito with one of four protozoan parasites: Plasmodium falciparum, vivax, malariae or ovale. The parasites enter the bloodstream and infect red blood cells where they multiply and infect more red blood cells. Symptoms usually occur 10 days to 4 weeks after infection and include anemia, high fevers, shaking chills, muscle pain, and nausea. Antimalarial agents used to treat malaria include Quinine, Quinidine, Mefloquine, Chloroquine, and Hydroxychloroquine. The effectiveness of the agents depends on which phase or phases of the Plasmodium life cycle is interrupted. In most cases, treatment outcome is expected to be good except in cases of a p. falciparum infection. Adverse effects from antimalaria medications include vomiting, diarrhea, headaches, cardiac arrhythmias, EKG abnormalities, deafness, damage to liver and kidney and muscle weakness. Source: NMS labs

LOINC Names Get Info

Fully-Specified Name
Plasmodium falciparum DNA:PrThr:Pt:{Specimen}:Ord:{Molgen}
Long Common Name
Plasmodium falciparum DNA [Presence] in Specimen by Molgen
Short Name
P falciparum DNA Spec Ql
Display Name
P. falciparum DNA Molgen Ql (Specimen)
Consumer Name Alpha Get Info
Plasmodium falciparum, Specimen

Part Model Get Info

  • Component
    Plasmodium falciparum DNA
    LP39414-5
    • Analyte
      Plasmodium falciparum DNA
      LP39414-5
      • Component Numerator
        Plasmodium falciparum DNA
        LP39414-5
        • Component Numerator Core
          Plasmodium falciparum
          LP14839-2
        • Component Numerator Core Suffix
          DNA
          LP32416-7
      • Component Denominator
        NULL
         
        • Component Denominator Core
          NULL
           
        • Component Denominator Core Suffix
          NULL
           
    • Challenge
      NULL
       
    • Adjustment
      NULL
       
    • Count
      NULL
       
  • Property
    PrThr
    LP217195-9
  • Time
    Pt
    LP6960-1
  • System
    {Specimen}
    LP451871-0
  • Scale
    Ord
    LP7751-3
  • Method
    {Molgen}
    LP452305-8

Basic Attributes

Class
MICRO
Type
Laboratory
First Released
Version 2.83
Last Updated
Version 2.83 (ADD)
Order vs. Observation
Both

Member of these Groups Get Info

LOINC GroupGroup Name
LG41640-0Plasmodium

LOINC Terminology Service (API) using HL7® FHIR® Get Info

CodeSystem lookup
https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=114740-4